BLPH - Bellerophon Therapeutics EPS misses by $0.01

Bellerophon Therapeutics (BLPH): Q3 GAAP EPS of -$0.84 misses by $0.01.Cash and cash equivalents of $54M.“Bellerophon continues to advance multiple development programs for its INOpulse® inhaled nitric oxide therapy,” said Fabian Tenenbaum, Chief Executive Officer of Bellerophon. “We are pleased with the rate of enrollment in our ongoing COViNOX Phase 3 clinical trial of INOpulse for the treatment of COVID-19. The results of a planned interim analysis are expected shortly, as the first 100 patients have now completed their 28-day assessment period. In support of our development and manufacturing plans in COVID-19, we have applied for government funding and are in discussions with a number of federal agencies, including Operation Warp Speed.” Press Release

For further details see:

Bellerophon Therapeutics EPS misses by $0.01